GO
Loading...

Covidien PLC

More

  • Jan 21- Jan 21- Covidien Plc said it would stop making a device for treating high blood pressure due to weak demand for the product, raising more doubts about the future of the novel technology.

  • Covidien to stop making hypertension devices Tuesday, 21 Jan 2014 | 9:28 AM ET

    Jan 21- Covidien Plc said it would stop making devices for treating high blood pressure due to weak industry-wide demand. Covidien's device is approved in Europe and is being tested in the United States. Covidien said it expects to record after-tax charges of $20- $25 million as a result of exiting the program.

  • Jan 9- Medtronic Inc's experimental device to treat high blood pressure failed to meet its main goal in a clinical trial, sending the company's shares down nearly 5 percent.

  • Early movers: AAL, TWC, DIS, AAPL & more Monday, 9 Dec 2013 | 7:35 AM ET

    Some of the names on the move ahead of the open.

  • One ethical fund's Four Commandments Tuesday, 12 Nov 2013 | 6:00 AM ET

    Doing well by doing good is an elusive goal, but George Schwartz seems to have figured out how to do well by not doing things he believes are bad.

  • Weak jobs report expected, but what if it's not? Thursday, 7 Nov 2013 | 7:11 PM ET
    People looking for work stand in line to apply for a job during a job fair in Miami on May 2.

    October's jobs report is expected to be one of the weakest of the year, distorted by the impact of the 16-day government shutdown.

  • IRS Disallows $2.86 Billion in Tyco Tax Deductions Tuesday, 2 Jul 2013 | 8:05 AM ET
    Tyco International Ltd. signage is displayed outside of the company's offices in Boca Raton, Florida, U.S.

    The IRS has informed Tyco that it has disallowed roughly $2.86 billion in interest and deductions recognized by the company in its U.S. returns for 1997-2000.

  • Early Movers: DIS, ZNGA, TYC, STZ, ONXX & More Tuesday, 2 Jul 2013 | 7:56 AM ET

    Some of the names on the move ahead of the open.

  • Covidien CEO on Pharma Spin-Off     Monday, 1 Jul 2013 | 4:45 PM ET

    Covidien President & CEO Jose Almeida discusses why now is the best time to separate the pharma business. "Covidien has been growing above market," he says.

  • Cramer: This Break-Up Creating Immense Value Friday, 14 Jun 2013 | 6:15 PM ET

    Jim Cramer believes this company is about to create immense value with the stroke of a pen.

  • Cramer: Break-Up Could Boost This Stock 19% Friday, 17 May 2013 | 6:02 PM ET

    Cramer’s convinced the best way to for this health care company to maximize shareholder value is to break up.

  • Why S&P 1,500 May Signal Stock Rally Has Peaked Friday, 25 Jan 2013 | 12:26 PM ET

    The S&P 500 regained the 1,500 level for the first time in more than five years, but that's a milestone that could also trigger a pause, analysts say.

  • Bulls Gear Up for Another Run at 1,500 on S&P Thursday, 24 Jan 2013 | 9:35 PM ET

    Wall Street's bull could take another run at the psychologically important 1,500 level as early as Friday, but that's a level that could also trigger a pause, analysts say.

  • Will Tech Earnings Charge Up the Stock Market Rally? Friday, 18 Jan 2013 | 8:33 PM ET
    Google Maps app for Apple ios.

    A flood of earnings reports, including major technology and industrial companies, could make or break the stock market’s surprise January rally in the week ahead.

  • Ryan: Is the Health Care Sector 'Healthy?' Monday, 7 Jan 2013 | 2:13 PM ET

    CNBC Contributor Barbara Ryan is taking the pulse of health care stocks at this year's "Woodstock" of health care.

  • Stocks to Watch: P, FB, MFRM & More Wednesday, 5 Dec 2012 | 8:07 AM ET

    Here are Wednesday's morning movers.

  • Analyst downgrades Johnson & Johnson to "sell" Tuesday, 9 Oct 2012 | 12:00 AM ET

    NEW YORK-- Goldman Sachs downgraded Johnson& Johnson, saying Tuesday that the current share price has captured all the potential for improved growth. However, Goldman analyst Jami Rubin wrote that Johnson& Johnson comes up short in the two areas she sees as likely to boost stock prices, new prescription drugs and capital allocation.

  • *Announces FDA 510 clearance and ce mark for Nellcor (TM) bedside. *Says new system will be available in the United States and throughout the eea. in the next few months.

  • Covidien completes $100M CNS Therapeutics deal Tuesday, 2 Oct 2012 | 4:35 PM ET

    NEW YORK-- Drug and medical device maker Covidien PLC said Tuesday it completed its $100 million purchase of CNS Therapeutics. Covidien announced it was buying CNS on Sept. 24. CNS is now part of Covidien's Mallinckrodt pharmaceuticals business.

  • Covidien CEO on Earnings & Obamacare     Thursday, 26 Jul 2012 | 6:25 PM ET

    Joe Almeida, Covidien plc chairman, president & CEO, discusses his company's medical device products and recent earnings, and the Supreme Court's health-care ruling.

Most Popular Video

Monday, 21 Apr 2014 | 7:42 AM ET

Jon Steinberg, BuzzFeed, provides a preview of tech earnings and explains why Apple shares are flat.

Monday, 21 Apr 2014 | 7:32 AM ET

Boris Schlossberg, BK Asset Management; Ed Keon, Quantitative Management Associates; and Krishna Guha, ISI Group, discuss the strong euro, the play on the Japanese yen and whether the markets are fairly valued.

Monday, 21 Apr 2014 | 7:19 AM ET

Garvis Toler, Dealogic, discusses what's driving the increase in tech IPOs as Alibaba readies its public debut.